EC
Euclidean Capital Portfolio holdings
AUM
$306M
This Quarter Return
-0.41%
1 Year Return
+16.69%
3 Year Return
+17.66%
5 Year Return
–
10 Year Return
–
AUM
$176M
AUM Growth
+$176M
(-15%)
Cap. Flow
-$14.6M
Cap. Flow
% of AUM
-8.27%
Top 10 Holdings %
Top 10 Hldgs %
99.04%
Holding
12
New
2
Increased
–
Reduced
5
Closed
1
Top Buys
| 1 |
Marqeta
MQ
|
$4.25M |
| 2 |
Vir Biotechnology
VIR
|
$1.69M |
Top Sells
| 1 |
PMV Pharmaceuticals
PMVP
|
$10M |
| 2 |
RAPT Therapeutics
RAPT
|
$7.43M |
| 3 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$1.52M |
| 4 |
Pinduoduo
PDD
|
$1.11M |
| 5 |
Oric Pharmaceuticals
ORIC
|
$436K |
Sector Composition
| 1 | Healthcare | 95.18% |
| 2 | Technology | 2.42% |
| 3 | Financials | 2.41% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PMV Pharmaceuticals
PMVP
$74.2M
| $54M | 30.69% |
2,336,909
-432,904
| -16% | -$10M |
|
2
Foghorn Therapeutics
FHTX
$286M
| $28.8M | 16.4% |
1,261,261
| – | – |
|
3
Alector
ALEC
$238M
| $20.3M | 11.52% |
980,894
| – | – |
|
4
Tenaya Therapeutics
TNYA
$184M
| $17.4M | 9.87% |
915,705
| – | – |
|
|
5
RAPT Therapeutics
RAPT
$188M
| $15.9M | 9.04% |
432,900
-202,277
| -32% | -$7.43M |
|
|
NGM
6
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $13.2M | 7.52% |
746,674
-85,600
| -10% | -$1.52M |
|
|
7
Oric Pharmaceuticals
ORIC
$994M
| $11M | 6.25% |
747,550
-29,643
| -4% | -$436K |
|
8
Surrozen
SRZN
$104M
| $5.17M | 2.94% |
802,964
-1
| -0% | -$6 |
|
|
9
Marqeta
MQ
$2.86B
| $4.25M | 2.42% |
+247,752
| New | +$4.25M |
|
10
First Financial Bancorp
FFBC
$2.51B
| $4.23M | 2.41% |
173,576
| – | – |
|
|
11
Vir Biotechnology
VIR
$686M
| $1.69M | 0.96% |
+40,257
| New | +$1.69M |
|
|
12
Pinduoduo
PDD
$171B
| – | – |
-12,262
| Closed | -$1.11M |
|